Abstract:Previous work led to the rational design, synthesis and testing of novel antifungal triazole analogues bearing alkynyl-methoxyl side chains. Tests of in vitro antifungal activity showed Candida albicans SC5314 and Candida glabrata 537 gave MIC values of ≤0.125 μg/mL for most of the compounds. Among these, compounds 16, 18, and 29 displayed broad-spectrum antifungal activity against seven human pathogenic fungal species, two fluconazole-resistant C. albicans isolates and two multi-drug resistant Candida auris isolates. Moreover, 0.5 μg/mL of 16, 18, and 29 was more effective than 2 μg/mL of fluconazole at inhibiting fungal growth of the strains tested. The most active compound (16) completely inhibited the growth of C. albicans SC5314 at 16 μg/mL for 24 h, affected biofilm formation and destroyed the mature biofilm at 64 μg/mL. Several Saccharomyces cerevisiae strains, overexpressing recombinant Cyp51s or drug efflux pumps, indicated 16, 18, and 29 targeted Cyp51 without being significantly affected by a common active site mutation, but were susceptible to target overexpression and efflux by both MFS and ABC transporters. GC-MS analysis demonstrated that 16, 18, and 29 interfered with the C. albicans ergosterol biosynthesis pathway by inhibition at Cyp51. Molecular docking studies elucidated the binding modes of 18 with Cyp51. The compounds showed low cytotoxicity, low hemolytic activity and favorable ADMT properties. Importantly, compound 16 showed potent in vivo antifungal efficacy in the G. mellonella infection model. Taken together, this study presents more effective, broad-spectrum, low toxicity triazole analogues that can contribute to the development of novel antifungal agents and help overcome antifungal resistance.

Design, Synthesis, and in Vitro Antifungal Evaluation of Novel Triazole Derivatives Bearing Alkynyl Side Chains

Design, synthesis and in vitro biological studies of novel triazoles with potent and broad-spectrum antifungal activity

Novel antifungal triazoles with alkynyl-methoxyl side chains: Design, synthesis, and biological activity evaluation.

Design, synthesis, and in vitro evaluation of novel antifungal triazoles containing substituted 1,2,3-triazole-methoxyl side chains

Design, synthesis and <i>in vitro</i> biological studies of novel triazoles with potent and broad-spectrum antifungal activity

Design, Synthesis, and in Vitro Evaluation of Novel Triazole Analogues Featuring Isoxazole Moieties As Antifungal Agents.

Synthesis, in Vitro Evaluation and Molecular Docking Studies of New Triazole Derivatives As Antifungal Agents.

Synthesis and antifungal evaluation of novel triazole derivatives bearing a pyrazole-methoxyl moiety

Molecular Docking, Design, Synthesis and Antifungal Activity Study of Novel Triazole Derivatives Containing the 1,2,3-Triazole Group

Molecular Docking, Design, Synthesis and Antifungal Activity Study of Novel Triazole Derivatives

Design, Synthesis, and In Vitro and In Vivo Antifungal Activity of Novel Triazoles Containing Phenylethynyl Pyrazole Side Chains

Design, synthesis and antifungal activity of novel triazole derivatives containing substituted 1,2,3-triazole-piperdine side chains.

Design, Synthesis, Evaluation and Optimization of Novel Azole Analogues As Potent Antifungal Agents

Synthesis, Molecular Docking, and Biological Evaluation of Novel Triazole Derivatives as Antifungal Agents

Design, synthesis, and antifungal activity of novel conformationally restricted triazole derivatives.

Structure-based design, synthesis, and antifungal activity of new triazole derivatives.

Design, Synthesis, and Antifungal Activity of 3-Substituted Triazole Derivatives

Design, synthesis and antifungal activities of novel 1,2,4-triazole derivatives.

Design, Synthesis and Antifungal Evaluation of 1-(2-(2,4-Difluorophenyl)-2-hydroxy-3-(1h-1,2,4-triazol-1-yl)propyl)-1h-1,2,4-triazol-5(4h)-one

New Triazole Derivatives Containing Substituted 1,2,3-Triazole Side Chains: Design, Synthesis and Antifungal Activity

Triazole Derivatives with Improved in Vitro Antifungal Activity over Azole Drugs